Caminiti SP, et al. - Researchers validated the [18F]FDG-PET metabolic signatures which support the diagnosis of dementia with Lewy bodies (DLB) near the first clinical evaluation. They retrospectively selected 72 patients from a large clinical cohort referred to the Department of Neurology and Nuclear Medicine at the San Raffaele Hospital (Milan, Italy) between 2010 and 2015, who had a final diagnosis of probable DLB. According to findings, the characteristic pattern of brain hypometabolism, which involves the occipital lobes and is obtained using suitable analytical methods, is a dependable biomarker of DLB, supporting its use in the existing diagnostic criteria. This also supports a review of the diagnostic flowchart for DLB and endorses the use of [18F]FDG-PET as a valuable biomarker that is very accurate for early diagnosis of DLB and differential diagnosis with other parkinsonian and dementia conditions. Investigators found that [18F]FDG-PET hypometabolism maps offered very high discriminatory power that discriminated DLB from Alzheimer’s disease dementia (ADD) and Parkinson’s disease (PD) conditions with an accuracy of > 90%. The evaluation of the hypometabolism pattern of [18F]FDG-PET at entry might shorten diagnostic time, leading to benefits for treatment options and patient management.